Product image of Mibi (Tetrafluoroborate) supplied by GNH India

Mibi

Active Ingredient:
Tetrafluoroborate
Origin:
EU

Mibi (Tetrafluoroborate)

Tetrafluoroborate, the active ingredient in Mibi, is a compound presented as an intravenous formulation for administration. Its therapeutic applications are not publicly disclosed.
GNH India supplies Mibi as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Radiopharmacy Laboratórium Kft.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mibi (tetrafluoroborate) currently has no publicly disclosed approved therapeutic indications.

  • No specific indication: No approved clinical use is listed for this product.
  • Investigational use: May be employed in research settings under controlled protocols.
  • Compassionate use: Could be considered in exceptional cases where no alternatives exist, subject to regulatory approval.

How It Works

  • The precise pharmacological mechanism of tetrafluoroborate when administered intravenously has not been publicly detailed. Available information indicates that the compound interacts with biological systems at a molecular level, but the specific targets, receptors, or pathways involved remain undisclosed in the public domain.

Side Effects

Adverse reaction information for Mibi is limited in publicly available sources.

Common Side Effects

  • Injection site discomfort: Mild pain or irritation at the site of administration.
  • Transient flushing: Temporary reddening of the skin.
  • Nausea: Mild feeling of queasiness.

Serious or Rare Side Effects

  • Hypersensitivity reaction: Signs may include rash, itching, or swelling.
  • Hemodynamic changes: Unusual drops or spikes in blood pressure.
  • Renal impairment: Potential impact on kidney function in susceptible individuals.

Precautions & Warnings

When handling Mibi, consider the following precautions.

  • Patient assessment: Evaluate medical history and current conditions before administration.
  • Monitoring: Observe vital signs during and after infusion.
  • Contraindications: Do not use in patients with known hypersensitivity to the product.
  • Pregnancy and lactation: Use only if clearly needed and after risk‑benefit evaluation.
  • Storage: Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Avoid Interactions

Potential drug interactions with Mibi have not been comprehensively documented.

Major Interactions (Avoid)

  • None identified: No major interaction warnings are currently available.

Moderate Interactions (Monitor Closely)

  • Concurrent IV therapies: Monitor for additive effects on vascular tone.
  • Anticoagulants: Observe coagulation parameters if used together.
  • Electrolyte-modifying agents: Check electrolyte balance during combined use.

Frequently Asked Questions

Mibi contains tetrafluoroborate and is currently listed without publicly disclosed approved therapeutic indications. It may be utilized in research or compassionate use contexts under appropriate regulatory oversight.

The exact mechanism of action for tetrafluoroborate when given intravenously has not been made public. Available data suggest it interacts at a molecular level, but specific targets or pathways have not been disclosed.

Dosing for Mibi is determined by the prescribing clinician based on the specific clinical scenario, patient characteristics, and regulatory guidance. No standard dose is publicly defined.

Safety data for tetrafluoroborate in pregnancy or lactation are not publicly available. Use should be limited to situations where the potential benefit justifies any possible risk, after thorough evaluation by a healthcare professional.

To request Mibi, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Because specific therapeutic indications and pharmacological data for Mibi are not publicly disclosed, direct comparisons with alternative agents are limited. Clinicians should evaluate any alternative based on available evidence, mechanism, safety profile and regulatory status.

Mibi should be stored at ambient temperature, kept in its original packaging, and protected from moisture and direct sunlight to maintain product integrity.

Mibi is supplied as an intravenous formulation and must be administered by a qualified healthcare professional using aseptic technique, following standard infusion protocols.

Serious risks, though not fully characterized, may include hypersensitivity reactions, hemodynamic instability, and potential renal impairment. Patients should be monitored closely during and after infusion.

Mibi should be avoided in individuals with known hypersensitivity to tetrafluoroborate or any of its excipients, and in patients where the risk outweighs any potential benefit, as determined by a qualified clinician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Tetrafluoroborate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT